O11 biomedical GmbH
- Area of Focus:
COPD, hypercapnia
- Competitive advantage:
Clear data on improved efficacy and obvious improved patient burden;
Outperforms standard of care including EU gold standard treatment NIV (non-invasive ventilation)
- Mode of action:
Breathing via the gut!
- Stage of development:
clear data in large animal hypercapnia model, “First in Patient” in Q1 2026
- Technology:
4 patents (transferrred), Operating in-house production (ISO 13485) scaled to market entry
- Raised so far:
9.7M$
- Team:
trusted and experienced in the fields business, pulmonology, production- and material knowledge, innovation management, IP, biology, QM/QC
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}